// App-Quantinova.ai

: DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer.

Researchers

Presenter

  • Tamim Niazi

Principal Investigators

  • Scott Williams

  • Ian D. Davis

  • Martin R. Stockler

  • Andrew James Martin

  • Hans T. Chung

  • Felicia Roncolato

  • Annie Ebacher

  • Eric Khoo

  • Jarad Martin

  • Tee Sin Lim

  • Simon Hughes

  • David Pryor

  • James W.F. Catto

  • Paul Kelly

  • Leily Gholam Rezaei

  • Scott C. Morgan

  • Ricardo A. Rendon

  • Christopher Sweeney

Medical Centers

  • Icon Cancer Centre - Gold Coast University Hospital, Gold Coast, Australia

  • Centre hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada

  • Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

  • Princess Alexandra Hospital, Brisbane, Australia

  • Bon Secours Radiotherapy Cork, in partnership with UPMC Hillman Cancer Centre, Cork, Ireland

  • Jewish General Hospital/ McGill Univeristy, Montreal, QC, Canada

  • Monash University Eastern Health Clinical School, Box Hill, VIC, Australia

  • Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

  • Chris O'Brien Lifehouse, Sydney, Australia

  • Guy's and St. Thomas' Hospital NHS Trust & School of Cancer and Pharmaceutical Sciences, King’s College London, London, United Kingdom

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • Fiona Stanley Hospital, Perth, Australia

  • Academic Radiology, The University of Sheffield, Sheffield, United Kingdom,

  • South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia

  • Calvary Mater Newcastle, Newcastle, Australia

  • Nova Scotia Health Authority and Dalhousie University, Halifax, NS, Canada

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

Locations

  • Canada

  • Australia

  • Ireland

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Controlled

Phase

  • III

Study Id's

  • NCT04136353

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved